CB-5083: Selective p97 Inhibitor for Tumor Growth Suppression

Introduction and Principle: Disrupting Protein Homeostasis with Precision

Protein homeostasis is fundamental to cellular health, balancing protein synthesis, folding, and degradation. Dysregulation of these pathways underlies numerous diseases, including cancer, where enhanced protein turnover supports malignant proliferation and survival. The AAA ATPase p97 (valosin-containing protein, VCP) sits at the nexus of these processes, orchestrating protein quality control via the ubiquitin-proteasome system and modulating endoplasmic reticulum (ER) functions. CB-5083 is a potent, selective, and orally bioavailable p97 inhibitor developed to precisely dissect these pathways and induce apoptosis in cancer cells by disrupting protein homeostasis.

Mechanistically, CB-5083 exhibits high affinity for the second ATPase domain of p97, acting as a competitive inhibitor with an IC₅₀ of 15.4 nM against wild-type p97. This selectivity allows researchers to interrogate the unfolded protein response (UPR) pathway, protein degradation machinery, and downstream caspase signaling with minimal off-target effects. The compound’s robust pharmacological profile has enabled its progression to phase 1 clinical trials for multiple myeloma and solid tumors, underscoring its translational relevance.

Step-by-Step Experimental Workflow and Protocol Enhancements

1. Compound Preparation and Storage

• CB-5083 is a solid compound (molecular weight 413.47), insoluble in water but highly soluble in DMSO (≥20.65 mg/mL) and ethanol (≥4.4 mg/mL).
• Prepare fresh stock solutions in DMSO for in vitro work. For in vivo studies, dilute the DMSO stock into suitable vehicles just prior to administration.
• Store powder at -20°C. Avoid long-term storage of solutions to maintain compound integrity.

2. In Vitro Assays: Cell Viability, Apoptosis, and Protein Degradation

• Seed cancer cell lines (e.g., HEK293T, A549, HCT116) at optimal densities in multiwell plates.
• Add CB-5083 at desired concentrations (10 nM – 5 μM) for dose-response studies. Published benchmarks indicate dose-dependent increases in cytosolic protein degradation and robust induction of apoptosis within 24–72 hours (see CB-5083: Selective p97 AAA-ATPase Inhibitor for Cancer Cells).
• For protein homeostasis disruption, measure ubiquitinated protein accumulation by immunoblot or ELISA. Quantify apoptosis using caspase-3/7 activity assays and annexin V/PI staining by flow cytometry.
• Monitor UPR activation by assessing CHOP and ATF4 expression, as well as eIF2α phosphorylation via Western blotting.

3. In Vivo Tumor Xenograft Models

• Establish xenografts in immunocompromised mice with human tumor cell lines (lung carcinoma, colorectal adenocarcinoma, or multiple myeloma).
• Administer CB-5083 orally at 10–60 mg/kg daily, as guided by previous studies (CB-5083: A Selective, Oral p97 Inhibitor for Protein Homeostasis).
• Evaluate tumor growth inhibition via caliper measurements or imaging. Histological analysis of tumor tissues can confirm UPR induction (e.g., increased CHOP) and apoptosis (caspase-3 cleavage, TUNEL staining).

This workflow enables robust assessment of p97 inhibition on tumor biology, protein degradation pathways, and the UPR in both cellular and whole-animal contexts.

Advanced Applications and Comparative Advantages

Deciphering the Protein Degradation Pathway and ER Homeostasis

CB-5083’s selectivity for p97 allows for nuanced interrogation of the protein quality control system. In the context of the recent study by Carrasquillo Rodríguez et al. (MBoC, July 2024 Special Issue), the ER’s role in protein and lipid homeostasis is highlighted, with p97 being a central player in ER-associated degradation (ERAD). The study demonstrates that protein quality control—mediated by p97 and its cofactors—directly impacts membrane synthesis and lipid storage, expanding the scope of CB-5083’s utility beyond cancer to metabolic research.

Unlike pan-proteasome inhibitors, CB-5083 offers:

• Targeted disruption of the selective p97 ATPase activity, minimizing broader proteasomal effects.
• Oral bioavailability, enabling chronic dosing or long-term studies in animal models.
• Quantified efficacy: In vivo, CB-5083 achieves up to 80% tumor growth inhibition in mouse xenografts, with significant induction of the unfolded protein response and apoptosis markers.
• Translational validation: Advanced to phase 1 clinical trials for multiple myeloma and solid tumor research, underscoring its relevance for preclinical and translational workflows.

Integrating Emerging Insights from Protein Homeostasis Research

CB-5083 is positioned at the vanguard of next-generation p97 inhibitors. In recent reviews (CB-5083: Redefining Translational Research on p97 and ER), its mechanistic specificity is contrasted with first-generation compounds, highlighting superior pharmacokinetics and reduced off-target toxicity. Furthermore, these articles complement the Carrasquillo Rodríguez et al. study by mapping the interplay between p97, the unfolded protein response, and ER lipid regulation, reinforcing the value of CB-5083 as a research tool for both cancer and metabolic disease models.

Troubleshooting and Optimization Tips for Reliable Outcomes

• Solubility Issues: Always prepare CB-5083 stocks in DMSO; avoid aqueous solvents. If precipitation is observed upon dilution, vortex thoroughly and ensure the final DMSO concentration does not exceed cell tolerance (typically <0.1% v/v).
• Compound Stability: Prepare fresh working stocks as repeated freeze-thaw cycles or prolonged storage in solution may reduce potency.
• Dose Selection: For cell-based assays, titrate CB-5083 across a range (e.g., 10 nM–5 μM) to determine the optimal window for your cell type. For xenograft studies, reference published in vivo dosing regimens and monitor animal weight/tolerability.
• Assay Timing: UPR and apoptosis markers typically peak 24–48 hours post-treatment. For protein degradation assays, shorter timepoints (6–12 hours) may reveal early mechanistic effects.
• Controls: Include vehicle (DMSO) controls and, where possible, a non-selective proteasome inhibitor (e.g., MG-132) to contextualize results.
• Interference with ER Lipid Studies: If investigating ER expansion or lipid storage (as in Carrasquillo Rodríguez et al.), consider co-treating with CB-5083 and monitoring both protein and lipid markers to dissect crosstalk between the protein degradation and lipid synthesis pathways.
• Batch-to-Batch Consistency: Source CB-5083 from trusted suppliers such as APExBIO to ensure high purity and reproducibility across experiments.

For further scenario-driven guidance and protocol optimization, the article CB-5083 (SKU B6032): Optimizing p97 Inhibition for Reliable Data provides evidence-based troubleshooting strategies that complement these recommendations.

Future Outlook: Expanding the Horizon of Protein Quality Control Research

The emergence of CB-5083 as a selective p97 AAA-ATPase inhibitor catalyzes new directions in cancer, metabolic, and ER stress research. As demonstrated by both preclinical models and the translational leap to clinical trials, targeting the protein degradation pathway and unfolded protein response holds promise for hard-to-treat malignancies and diseases of ER dysfunction. The integration of CB-5083 into advanced experimental designs—such as combinatorial screens with ER lipid regulators or CRISPR-based genetic perturbations—will further unravel the complexity of protein homeostasis disruption and caspase signaling pathway activation.

Moreover, as highlighted by Carrasquillo Rodríguez et al., the differential regulation of ER membrane synthesis and lipid storage by protein quality control machinery opens new avenues for dissecting the interplay between proteostasis and lipid metabolism. CB-5083’s ability to inhibit tumor xenograft growth, induce apoptosis, and activate the UPR makes it a cornerstone for both basic and translational research. As the landscape of p97 inhibitors evolves, researchers can expect further enhancements in selectivity, safety, and therapeutic scope—solidifying CB-5083’s role as an essential tool in the molecular biology toolkit.

For more in-depth mechanistic insights and cutting-edge protocol guidance, explore the curated resources:

• CB-5083: Selective p97 AAA-ATPase Inhibitor for Cancer Cells (mechanistic specificity, benchmarks)
• CB-5083: A Selective, Oral p97 Inhibitor for Protein Homeostasis (workflow integration)
• CB-5083: Redefining Translational Research on p97 and ER (visionary outlook)

To ensure the highest standards in your research, trust APExBIO for your CB-5083 supply and benefit from their expertise in supporting advanced experimental workflows.